Detalhe da pesquisa
1.
Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy.
Leuk Lymphoma
; 63(4): 928-938, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35147482
2.
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
Dis Markers
; 2022: 3132941, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36051360
3.
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.
Blood Cancer J
; 11(10): 175, 2021 10 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34718324